GILD Stock Recent News
GILD LATEST HEADLINES
LOS ANGELES--(BUSINESS WIRE)--AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention.
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS)'s twice-yearly injectable HIV prevention drug lenacapavir is on track for a solid launch after being officially approved by the US Food and Drug Administration (FDA) on Wednesday, analysts at Jefferies believe. Lenacapavir, marketed as Yeztugo, is the first pre-exposure prophylaxis (PrEP) drug requiring only two treatments per year, offering a significant convenience advantage over daily oral PrEP and cabotegravir, which requires six injections per year.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company's injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the United States for people who need or want PrEP. Data show that ≥99.9% of partici.
The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending the decades-long epidemic caused by the virus.
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Despite a recent setback with an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P 500's modest 2% gain. The company is actively collaborating with authorities to resolve the recent issues and remains focused on improving profitability.
NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ:GILD). Investors who purchased Gilead securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GILD.
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.